Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Li, Lili ^a   Su, Xianwei ^a   Choi, Gigi C G ^a   Cao, Ya ^b   Ambinder, Richard F ^c   Tao, Qian ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b The First People s Hospital of Changde City)   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; IMMEDIATE EARLY PROTEIN BZLF1; TRICHOSTATIN A; BRLF1 PROTEIN, HUMAN HERPESVIRUS 4; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; IMMEDIATE EARLY PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; BHRF1 GENE; BISULFITE GENOMIC SEQUENCING; BLLF1 GENE; BRLF1 GENE; BZLF1 GENE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EPITHELIUM TUMOR; EPSTEIN BARR VIRUS; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMEDIATE EARLY GENE; LYMPHATIC SYSTEM TUMOR; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; B LYMPHOCYTE; EPITHELIUM CELL; GENETICS; METABOLISM; NATURAL KILLER CELL; NEOPLASM; TUMOR CELL LINE; VIROLOGY;

B-LYMPHOCYTES; CELL LINE, TUMOR; DNA METHYLATION; EPITHELIAL CELLS; GENES, IMMEDIATE-EARLY; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; KILLER CELLS, NATURAL; NEOPLASMS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 84858966696     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-125     Document Type: Article

References (40)

1. Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006, 11:2672-2713. 10.2741/2000, 16720343.
2. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004, 4(10):757-768. 10.1038/nrc1452, 15510157.
3. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003, 22(33):5108-5121. 10.1038/sj.onc.1206556, 12910248.
4. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2005, 15(3):149-156. 10.1002/rmv.456, 15546128.
5. Niller HH, Wolf H, Ay E, Minarovits J. Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease. Adv Exp Med Biol 2011, 711:82-102. 10.1007/978-1-4419-8216-2_7, 21627044.
6. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009, 19(3):158-164. 10.1016/j.semcancer.2009.02.012, 19429479.
7. Ambinder RF, Robertson KD, Tao Q. DNA methylation and the Epstein-Barr virus. Semin Cancer Biol 1999, 9(5):369-375. 10.1006/scbi.1999.0137, 10547345.
8. Flower K, Hellen E, Newport MJ, Jones S, Sinclair AJ. Evaluation of a prediction protocol to identify potential targets of epigenetic reprogramming by the cancer associated Epstein Barr virus. PLoS One 2010, 5(2):e9443. 10.1371/journal.pone.0009443, 2829078, 20195470.
9. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J. Epigenetic regulation of latent Epstein-Barr virus promoters. Biochim Biophys Acta 2010, 1799(3-4):228-235.
10. Tao Q, Robertson KD. Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109(1):53-63. 10.1016/S1521-6616(03)00198-0, 14585276.
11. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007, 9(12):1-24.
12. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004, 22(8):1373-1381. 10.1200/JCO.2004.04.185, 15007085.
13. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 1998, 72(9):7075-7083. 109928, 9696800.
14. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 1999, 155(2):619-625. 10.1016/S0002-9440(10)65157-7, 1866850, 10433954.
15. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC. Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. PLoS Pathog 2009, 5(3):e1000356. 10.1371/journal.ppat.1000356, 2654727, 19325883.
16. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 2004, 36(10):1099-1104. 10.1038/ng1424, 15361873.
17. Karlsson QH, Schelcher C, Verrall E, Petosa C, Sinclair AJ. Methylated DNA recognition during the reversal of epigenetic silencing is regulated by cysteine and serine residues in the Epstein-Barr virus lytic switch protein. PLoS Pathog 2008, 4(3):e1000005. 10.1371/journal.ppat.1000005, 2267006, 18369464.
18. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM, Lee JC. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999, 83(1):121-126. 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F, 10449618.
19. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, Yoon SK, Kim WH, Park JG, Lee SK. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer. Virology 2004, 320(2):330-336. 10.1016/j.virol.2003.12.005, 15016554.
20. Oh ST, Cha JH, Shin DJ, Yoon SK, Lee SK. Establishment and characterization of an in vivo model for Epstein-Barr virus positive gastric carcinoma. J Med Virol 2007, 79(9):1343-1348. 10.1002/jmv.20876, 17607773.
21. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004, 23(27):4793-4806. 10.1038/sj.onc.1207632, 15122337.
22. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006, 25(7):1070-1080. 10.1038/sj.onc.1209154, 16247458.
23. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 2007, 26(6):934-944. 10.1038/sj.onc.1209839, 16862168.
24. Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, Li H, Shu XS, Liu W, Luo B, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009, 69(12):5194-5201. 10.1158/0008-5472.CAN-08-3694, 19509237.
25. Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J, Srivastava G, Ng MH, Fukagawa T, Wu X, et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res 2010, 70(16):6516-6526. 10.1158/0008-5472.CAN-09-4566, 20682794.
26. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002, 11(18):2091-2102. 10.1093/hmg/11.18.2091, 12189161.
27. Pritchett RF, Hayward SD, Kieff ED. DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness. J Virol 1975, 15(3):556-559. 354493, 163373.
28. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993, 90(18):8479-8483. 10.1073/pnas.90.18.8479, 47380, 8397406.
29. Woodcock DM, Adams JK, Cooper IA. Characteristics of enzymatic DNA methylation in cultured cells of human and hamster origin, and the effect of DNA replication inhibition. Biochim Biophys Acta 1982, 696(1):15-22.
30. Chang PJ, Chang YS, Liu ST. Role of Rta in the translation of bicistronic BZLF1 of Epstein-Barr virus. J Virol 1998, 72(6):5128-5136. 110081, 9573284.
31. Chen C, Li D, Guo N. Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol Ther 2009, 8(11):987-995.
32. Heather J, Flower K, Isaac S, Sinclair AJ. The Epstein-Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol 2009, 90(Pt 6):1450-1454. 2885059, 19264650.
33. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol 2005, 79(12):7338-7348. 10.1128/JVI.79.12.7338-7348.2005, 1143640, 15919888.
34. Bergbauer M, Kalla M, Schmeinck A, Gobel C, Rothbauer U, Eck S, Benet-Pages A, Strom TM, Hammerschmidt W. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog 2010, 6(9):e1001114. 10.1371/journal.ppat.1001114, 2944802, 20886097.
35. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5(1):37-50. 10.1038/nrd1930, 16485345.
36. Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res 2011, 67:1-23.
37. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429(6990):457-463. 10.1038/nature02625, 15164071.
38. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29(15):1987-1996. 10.1200/JCO.2010.30.9245, 21483003.
39. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ades L, et al. Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. J Clin Oncol 2011, 29(24):3322-3327. 10.1200/JCO.2011.35.8135, 21788559.
40. Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010, 31(11):536-546. 10.1016/j.tips.2010.08.001, 2967479, 20846732.